Relação entre doença hepática gordurosa não alcoólica e alterações cardíacas

Autores

  • Milena Nascimento Universidade Federal de Mato Grosso, Campus de Sinop
  • Cristina Schmitt Gregolin Universidade Federal de Mato Grosso, Campus de Sinop
  • Renata Azevedo Melo Luvizotto Universidade Federal de Mato Grosso, Campus de Sinop
  • Antonio Carlos Cicogna Faculdade de Medicina - UNESP - Campus Botucatu
  • Andre Ferreira Nascimento Universidade Federal de Mato Grosso, Campus de Sinop

DOI:

https://doi.org/10.36560/14420211248

Palavras-chave:

nonalcoholic fatty liver disease, cardiac remodeling, cardiac dysfunction.

Resumo

A doença hepática gordurosa não alcoólica (DHGNA) é considerada a doença hepática crônica mais prevalente em todo o mundo, sendo um importante fator de risco para o desenvolvimento de doenças cardiovasculares. A doença arterial coronariana é reconhecida como a primeira causa do aumento de mortalidade e morbidade em pacientes com DHGNA. No entanto, diversas evidências apontam que a DHGNA não afeta apenas os vasos sanguíneos, mas também a estrutura e função do coração, tanto em adultos quanto crianças, chamando atenção para o fato de o comprometimento cardíaco vir a ser um grande fator de risco para a piora do prognóstico e qualidade de vida dos portadores de DHGNA. Nesta revisão narrativa nós descrevemos a associação entre DHGNA e o comprometimento do coração. Em adição, apresentamos uma visão fisiopatológica envolvida nessa relação.

Referências

ADAMS, L.A., ANSTEE, Q.M., TILG, H., TARGHER, G. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases. Gut 66(6):1138–1153, 2017. doi: 10.1136/gutjnl-2017-313884.

ANGULO, P. Nonalcoholic Fatty Liver Disease. N Engl J Med 346(16):1221–1231, 2002. doi: 10.1056/NEJMra011775.

ANSTEE, Q.M., TARGHER, G., DAY, C.P. Progression of NAFLD to diabetes mellitus, cardiovascular disease or cirrhosis. Nat Rev Gastroenterol Hepatol 10(6):330–344, 2013. doi: 10.1038/nrgastro.2013.41.

ARGO, C.K., CALDWELL, S.H. Epidemiology and Natural History of Non-Alcoholic Steatohepatitis. Clin Liver Dis 13(4):511–531, 2009. doi: 10.1016/j.cld.2009.07.005.

BAKTIR, A.O., SARLI, B., ALTEKIN, R.E., KARAMAN, A., ARINC, H., SAGLAM, H. et al. Non alcoholic steatohepatitis is associated with subclinical impairment in left ventricular function measured by speckle tracking echocardiography. Anadolu Kardiyol Dergisi/The Anatol J Cardiol 15(2):137–142, 2015. doi: 10.5152/akd.2014.5212.

BARTEKOVA, M., RADOSINSKA, J., JELEMENSKY, M., DHALLA, N.S. Role of cytokines and inflammation in heart function during health and disease. Heart Fail Rev 23(5):733–758, 2018. doi: 10.1007/s10741-018-9716-x.

BEKLER, A., GAZI, E., ERBAG, G., BINNETOGLU, E., BARUTCU, A., SEN, H. et al. Right ventricular function and its relationship with grade of hepatosteatosis in non-alcoholic fatty liver disease: cardiovascular topic. Cardiovasc J Afr 26(3):109–113, 2015. doi: 10.5830/CVJA-2014-068.

BONAPACE, S., PERSEGHIN, G., MOLON, G., CANALI, G., BERTOLINI, L., ZOPPINI, G. et al. Nonalcoholic Fatty Liver Disease Is Associated With Left Ventricular Diastolic Dysfunction in Patients With Type 2 Diabetes. Diabetes Care 35(2):389–395, 2012. doi: 10.2337/dc11-1820.

BONCI, E., CHIESA, C., VERSACCI, P., ANANIA, C., SILVESTRI, L., PACIFICO, L. Association of Nonalcoholic Fatty Liver Disease with Subclinical Cardiovascular Changes: A Systematic Review and Meta-Analysis. Biomed Res Int 2015:1–11, 2015. doi: 10.1155/2015/213737.

BORGES-CANHA, M., NEVES, J.S., LIBÂNIO, D., VON-HAFE, M., VALE, C., ARAÚJO-MARTINS, M. et al. Association between nonalcoholic fatty liver disease and cardiac function and structure—a meta-analysis. Endocrine 66(3):467–476, 2019. doi: 10.1007/s12020-019-02070-0.

BRUNT, E. Nonalcoholic Fatty Liver Disease: Pros and Cons of Histologic Systems of Evaluation. Int J Mol Sci 17(1):97, 2016. doi: 10.3390/ijms17010097.

CAI, J., ZHANG, X-J., JI, Y-X., ZHANG, P., SHE, Z-G., LI, H. Nonalcoholic Fatty Liver Disease Pandemic Fuels the Upsurge in Cardiovascular Diseases. Circ Res 126(5):679–704, 2020. doi: 10.1161/CIRCRESAHA.119.316337.

CANADA, J.M., ABBATE, A., COLLEN, R., BILLINGSLEY, H., BUCKLEY, L.F., CARBONE, S. et al. Relation of Hepatic Fibrosis in Nonalcoholic Fatty Liver Disease to Left Ventricular Diastolic Function and Exercise Tolerance. Am J Cardiol 123(3):466–473, 2019. doi: 10.1016/j.amjcard.2018.10.027

CASSIDY, S., HALLSWORTH, K., THOMA, C., MACGOWAN, G.A., HOLLINGSWORTH, K.G., DAY, C.P. et al. Cardiac structure and function are altered in type 2 diabetes and Non-alcoholic fatty liver disease and associate with glycemic control. Cardiovasc Diabetol 14(1):23, 2015. doi: 10.1186/s12933-015-0187-2

CHALASANI, N., YOUNOSSI, Z., LAVINE, J.E., CHARLTON, M., CUSI, K., RINELLA, M. et al. The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67(1):328–357, 2018. doi: 10.1002/hep.29367.

CHUNG, G.E., LEE, J-H., LEE, H., KIM, M.K., YIM. J.Y., CHOI, S-Y. et al. Nonalcoholic fatty liver disease and advanced fibrosis are associated with left ventricular diastolic dysfunction. Atherosclerosis 272:137–144, 2018. doi: 10.1016/j.atherosclerosis.2018.03.027.

CLARK, J.M., BRANCATI, F.L., DIEHL, A.M. Nonalcoholic fatty liver disease. Gastroenterology 122(6):1649–1657, 2002. doi: 10.1053/gast.2002.33573.

COTTER, T.G., RINELLA, M. Nonalcoholic Fatty Liver Disease 2020: The State of the Disease. Gastroenterology 158(7):1851–1864, 2020. doi: 10.1053/j.gastro.2020.01.052.

DINIZ, T.B.F., JESUS, R.N., JIMENEZ, L.S., PAREJA, J.C., CHAIM, E.A., CAZZO, E. Non-Alcoholic Fatty Liver Disease Is Associated with Impairment of Ejection Fraction Among Individuals with Obesity Undergoing Bariatric Surgery: Results of a Cross-Sectional Study. Obes Surg 30(2):456–460, 2020. doi: 10.1007/s11695-019-04179-7.

DONG, Y. Assessment of left ventricular function in type 2 diabetes mellitus patients with non-alcoholic fatty liver disease by three-dimensional speckle tracking echocardiography. Anatol J Cardiol 23(1):41-48. doi: 10.14744/AnatolJCardiol.2019.66805. doi: 10.14744/AnatolJCardiol.2019.66805.

DONNELLY, K.L., SMITH, C.I., SCHWARZENBERG, S.J., JESSURUN, J., BOLDT, M.D., PARKS, E.J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J Clin Invest 115(5):1343–1351, 2005. doi: 10.1172/JCI23621.

DUARTE, S.M.B., STEFANO, J.T., OLIVEIRA, C.P. Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). Ann Hepatol 18(3):416–421, 2019. doi: 10.1016/j.aohep.2019.04.006.

DUNCAN, D.J., YANG, Z., HOPKINS, P.M., STEELE, D.S., HARRISON, S.M. TNF-α and IL-1β increase Ca2+ leak from the sarcoplasmic reticulum and susceptibility to arrhythmia in rat ventricular myocytes. Cell Calcium 47(4):378–386, 2010. doi: 10.1016/j.ceca.2010.02.002.

EKSTEDT, M., HAGSTRÖM, H., NASR, P., FREDRIKSON, M., STÅL, P., KECHAGIAS, S. et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 61(5):1547–1554, 2015. doi: 10.1002/hep.27368.

FALLO, F., DALLA POZZA, A., SONINO, N., LUPIA, M., TONA, F., FEDERSPIL, G. et al. Non-alcoholic fatty liver disease is associated with left ventricular diastolic dysfunction in essential hypertension. Nutr Metab Cardiovasc Dis 19(9):646–653, 2009. doi: 10.1016/j.numecd.2008.12.007.

FINTINI, D., CHINALI, M., CAFIERO, G., ESPOSITO, C., GIORDANO, U., TURCHETTA, A. et al. Early left ventricular abnormality/dysfunction in obese children affected by NAFLD. Nutr Metab Cardiovasc Dis 24(1):72–74, 2014. doi: 10.1016/j.numecd.2013.06.005.

FORLANO, R., MULLISH, B.H., NATHWANI, R., DHAR, A., THURSZ, M., MANOUSOU, P. Non-Alcoholic Fatty Liver Disease and Vascular Disease. Curr Vasc Pharmacol 18, 2020. doi: 10.2174/1570161118666200318103001.

FOTBOLCU, H., YAKAR, T., DUMAN, D., KARAAHMET, T., TIGEN, K., CEVIK, C. et al. Impairment of the left ventricular systolic and diastolic function in patients with non-alcoholic fatty liver disease. Cardiol J 17(5):457–463, 2010.

GHABEN, A.L., SCHERER, P.E. Adipogenesis and metabolic health. Nat Rev Mol Cell Biol 20(4):242–458, 2019. doi: 10.1038/s41580-018-0093-z.

GOLAND, S., SHIMONI, S., ZORNITZKI, T., KNOBLER, H., AZOULAI, O., LUTATY, G. et al. Cardiac Abnormalities as a New Manifestation of Nonalcoholic Fatty Liver Disease: Echocardiographic and Tissue Doppler Imaging Assessment. J Clin Gastroenterol 40(10):949–955, 2006. doi: 10.1097/01.mcg.0000225668.53673.e6.

HAGIWARA, Y., MIYOSHI, S., FUKUDA, K., NISHIYAMA, N., IKEGAMI, Y., TANIMOTO, K. et al. SHP2-mediated signaling cascade through gp130 is essential for LIF-dependent ICaL, [Ca2+]i transient, and APD increase in cardiomyocytes. J Mol Cell Cardiol 43(6):710–716, 2007. doi: 10.1016/j.yjmcc.2007.09.004.

HALLSWORTH, K., HOLLINGSWORTH, K.G., THOMA, C., JAKOVLJEVIC, D., MACGOWAN, G.A., ANSTEE, Q.M. et al. Cardiac structure and function are altered in adults with non-alcoholic fatty liver disease. J Hepatol 58(4):757–762, 2013. doi: 10.1016/j.jhep.2012.11.015.

HUANG, J., HUANG, Q., CHEN, X-Z., ZHOU, F., HE, J-Q., WANG, X-L. A study of the relationship between cardiac diastolic function and liver function in patients with nonalcoholic fatty liver disease. World Chinese J Dig 17(21):2198, 2009. doi: http://dx.doi.org/10.11569/wcjd.v17.i21.2198

JANCZEWSKI, A.M., KADOKAMI, T., LEMSTER, B., FRYE, C.S., MCTIERNAN, C.F., FELDMAN, A.M. Morphological and functional changes in cardiac myocytes isolated from mice overexpressing TNF-α. Am J PhysiolCirc Physiol 284(3):H960–969, 2003. doi: 10.1152/ajpheart.0718.2001.

JUDE, B., VETEL, S., GIROUX-METGES, M.A., PENNEC, J.P. Rapid negative inotropic effect induced by TNF-α in rat heart perfused related to PKC activation. Cytokine 107:65–69, 2018. doi: 10.1016/j.cyto.2017.11.015.

JUNG, J.Y., PARK, S.K., RYOO, J-H., OH, C-M., KANG, J.G., LEE, J-H. et al. Effect of non-alcoholic fatty liver disease on left ventricular diastolic function and geometry in the Korean general population. Hepatol Res 47(6):522–532, 2017. doi: 10.1111/hepr.12770.

KARABAY, C.Y., KOCABAY, G., KALAYCI, A., COLAK, Y., ODUNCU, V., AKGUN, T. et al. Impaired left ventricular mechanics in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol 26(3):325–331, 2014. doi: 10.1097/MEG.0000000000000008.

KASWALA, D.H., LAI, M., AFDHAL, N.H. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016. Dig Dis Sci 61(5):1356–1364, 2016. doi: 10.1007/s10620-016-4079-4.

KIM, N.H., PARK, J., KIM, S.H., KIM, Y.H., KIM, D.H., CHO, G-Y. et al. Non-alcoholic fatty liver disease, metabolic syndrome and subclinical cardiovascular changes in the general population. Heart 100(12):938–943, 2014.

KIM, W.R., LAKE, J.R., SMITH, J.M., SCHLADT, D.P., SKEANS, M.A., HARPER, A.M. et al. OPTN/SRTR 2016 Annual Data Report: Liver. Am J Transplant 18:172–253, 2018. doi: 10.1111/ajt.14559.

KLEINER, D., BRUNT, E. Nonalcoholic Fatty Liver Disease: Pathologic Patterns and Biopsy Evaluation in Clinical Research. Semin Liver Dis 32(01):3–13, 2012. doi: 10.1055/s-0032-1306421.

KLEINER, D.E., BRUNT, E.M., WILSON, L.A., BEHLING, C., GUY, C., CONTOS, M. et al. Association of Histologic Disease Activity With Progression of Nonalcoholic Fatty Liver Disease. JAMA Netw Open 2(10):e1912565, 2019. doi: 10.1001/jamanetworkopen.2019.12565.

KO, H.J., ZHANG, Z., JUNG, D.Y., JUN, J.Y., MA, Z., JONES, K.E. et al. Nutrient Stress Activates Inflammation and Reduces Glucose Metabolism by Suppressing AMP-Activated Protein Kinase in the Heart. Diabetes 58(11):2536–2546, 2009. doi: 10.2337/db08-1361.

LAUTAMÄKI, R., BORRA, R., IOZZO, P., KOMU, M., LEHTIMÄKI, T., SALMI, M. et al. Liver steatosis coexists with myocardial insulin resistance and coronary dysfunction in patients with type 2 diabetes. Am J Physiol Metab 291(2):E282–290, 2006. doi: 10.1152/ajpendo.00604.2005.

LEE, H., KIM, G., CHOI, Y.J., HUH, B.W., LEE, B-W., KANG, E.S. et al. Association between Non-Alcoholic Steatohepatitis and Left Ventricular Diastolic Dysfunction in Type 2 Diabetes Mellitus. Diabetes Metab J 44(2):267, 2020. doi: 10.4093/dmj.2019.0001.

LEE, Y-H., KIM, K.J., YOO, M.E., KIM, G., YOON, H-J., JO, K. et al. Association of non-alcoholic steatohepatitis with subclinical myocardial dysfunction in non-cirrhotic patients. J Hepatol 68(4):764–772, 2018. doi: 10.1016/j.jhep.2017.11.023.

LIU, Y., NEUMANN, D., GLATZ, J.F.C., LUIKEN, J.J.F.P. Molecular mechanism of lipid-induced cardiac insulin resistance and contractile dysfunction. Prostaglandins, Leukot Essent Fat Acids 136:131–141, 2018. doi: 10.1016/j.plefa.2016.06.002.

LONGO, M., ZATTERALE, F., NADERI, J., PARRILLO, L., FORMISANO, P., RACITI, G.A. et al. Adipose Tissue Dysfunction as Determinant of Obesity-Associated Metabolic Complications. Int J Mol Sci 20(9):2358, 2019. doi: 10.3390/ijms20092358.

LOPASCHUK, G.D., USSHER, J.R., FOLMES, C.D.L., JASWAL, J.S., STANLEY, W.C. Myocardial Fatty Acid Metabolism in Health and Disease. Physiol Rev 90(1):207–258, 2010. doi: 10.1152/physrev.00015.2009.

LUDWIG, J., VIGGIANO, T.R., MCGILL, D.B., OH, B.J. Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. Mayo Clin Proc 55(7):434–438, 1980.

MANTOVANI, A., PERNIGO, M., BERGAMINI, C., BONAPACE, S., LIPARI, P., PICHIRI, I. et al. Nonalcoholic Fatty Liver Disease Is Independently Associated with Early Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes. Chen X, editor. PLoS One 10(8):e0135329, 2015. doi: 10.1371/journal.pone.0135329.

MANTOVANI, A., SCORLETTI, E., MOSCA, A., ALISI, A., BYRNE, C.D., TARGHER, G. Complications, morbidity and mortality of nonalcoholic fatty liver disease. Metabolism 154170, 2020. doi: 10.1016/j.metabol.2020.154170. doi: 10.1016/j.metabol.2020.154170.

MARRA, F., SVEGLIATI-BARONI, G. Lipotoxicity and the gut-liver axis in NASH pathogenesis. J Hepatol 68(2):280–295, 2018. doi: 10.1016/j.jhep.2017.11.014.

MATTEONI, C., YOUNOSSI, Z., GRAMLICH, T., BOPARAI, N., LIU, Y., MCCULLOUGH, A. Nonalcoholic fatty liver disease: A spectrum of clinical and pathological severity. Gastroenterology 116(6):1413–1419, 1999. doi: 10.1016/s0016-5085(99)70506-8.

METWALY, A., KHALIK, A.A., NASR, F.M., SABRY A. I., GOUDA, M.F., HASSAN, M. Brain Natriuretic Peptide in Liver Cirrhosis and Fatty Liver: Correlation with Cardiac Performance. Electron physician 8(2):1984–1993, 2016. doi: 10.19082/1984. doi: 10.19082/1984.

NISHIDA, K., OTSU, K. Inflammation and metabolic cardiomyopathy. Cardiovasc Res 113(4):389–398, 2017. doi: 10.1093/cvr/cvx012.

PACIFICO, L., DI MARTINO, M., DE MERULIS, A., BEZZI, M., OSBORN, J.F., CATALANO, C. et al. Left ventricular dysfunction in obese children and adolescents with nonalcoholic fatty liver disease. Hepatology 59(2):461–470, 2014. doi: 10.1002/hep.26610.

PERSEGHIN, G., LATTUADA, G., DE COBELLI, F., ESPOSITO, A., BELLONI, E., NTALI, G. et al. Increased mediastinal fat and impaired left ventricular energy metabolism in young men with newly found fatty liver. Hepatology 47(1):51–58, 2007. doi: 10.1002/hep.21983.

PETTA, S., ARGANO, C., COLOMBA, D., CAMMÀ, C., DI MARCO, V., CABIBI, D. et al. Epicardial fat, cardiac geometry and cardiac function in patients with non-alcoholic fatty liver disease: Association with the severity of liver disease. J Hepatol 62(4):928–933, 2015. doi: 10.1016/j.jhep.2014.11.030.

PRABHU, S.D. Cytokine-Induced Modulation of Cardiac Function. Circ Res 95(12):1140–1153, 2004. doi: 10.1161/01.RES.0000150734.79804.92.

QIN, C.X., SLEABY, R., DAVIDOFF, A.J., BELL, J.R., DE BLASIO, M.J., DELBRIDGE, L.M. et al. Insights into the role of maladaptive hexosamine biosynthesis and O-GlcNAcylation in development of diabetic cardiac complications. Pharmacol Res 116:45–56, 2017. doi: 10.1016/j.phrs.2016.12.016.

RIJZEWIJK, L.J., JONKER, J.T., VAN DER MEER, R.W., LUBBERINK, M., DE JONG, H.W., ROMIJN, J.A. et al. Effects of Hepatic Triglyceride Content on Myocardial Metabolism in Type 2 Diabetes. J Am Coll Cardiol 56(3):225–233, 2010. doi: 10.1016/j.jacc.2010.02.049.

SALUJA, M., KUMAR, K., SWAMI, Y.K., MEENA, S.R., GOYAL, S. Association between Non- alcoholic Fatty Liver Disease and Left Ventricular Diastolic Dysfunction in Patients of Type 2 Diabetes. J Assoc Physicians India 67(8):20–24, 2019.

SARMA AK. Echocardiographic evaluation in non-alcoholic fatty liver disease in population in an industrial hopsital. Indian Heart J 66:S61, 2014. doi: https://doi.org/10.1016/j.ihj.2014.10.170.

SCHUPPAN, D., AFDHAL, N.H. Liver cirrhosis. Lancet 371(9615):838–851, 2008. doi: 10.1016/S0140-6736(08)60383-9.

SERT, A., AYPAR, E., PIRGON, O., YILMAZ, H., ODABAS, D., TOLU, I. Left Ventricular Function by Echocardiography, Tissue Doppler Imaging, and Carotid Intima-Media Thickness in Obese Adolescents With Nonalcoholic Fatty Liver Disease. Am J Cardiol 112(3):436–443, 2013. doi: 10.1016/j.amjcard.2013.03.056.

SHARPTON, S.R., AJMERA, V., LOOMBA, R. Emerging Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease: From Composition to Function. Clin Gastroenterol Hepatol 17(2):296–306, 2019. doi: 10.1016/j.cgh.2018.08.065.

SIMON, T.G., BAMIRA, D.G., CHUNG, R.T., WEINER, R.B., COREY, K.E. Nonalcoholic Steatohepatitis is Associated with Cardiac Remodeling and Dysfunction. Obesity 25(8):1313–1316, 2017. doi: 10.1002/oby.21879.

SINGH, G.K., VITOLA, B.E., HOLLAND, M.R., SEKARSKI, T., PATTERSON, B.W., MAGKOS, F. et al. Alterations in Ventricular Structure and Function in Obese Adolescents with Nonalcoholic Fatty Liver Disease. J Pediatr 162(6):1160-1168.e1, 2013. doi: 10.1016/j.jpeds.2012.11.024.

STAHL, E.P., DHINDSA, D.S., LEE, S.K., SANDESARA, P.B., CHALASANI, N.P., SPERLING, L.S. Nonalcoholic Fatty Liver Disease and the Heart. J Am Coll Cardiol 73(8):948–963, 2019. doi: 10.1016/j.jacc.2018.11.050.

STANLEY, W.C., RECCHIA, F.A., LOPASCHUK, G.D. Myocardial Substrate Metabolism in the Normal and Failing Heart. Physiol Rev 85(3):1093–1129, 2005. doi: 10.1152/physrev.00006.2004.

SUNBUL, M., KIVRAK, T., DURMUS, E., AKIN, H., AYDIN, Y., ERGELEN, R. et al. Nonalcoholic Steatohepatitis Score is an Independent Predictor of Right Ventricular Dysfunction in Patients with Nonalcoholic Fatty Liver Disease. Cardiovasc Ther 33(5):294–299, 2015. doi: 10.1111/1755-5922.12145.

TILG, H., MOSCHEN, A.R. Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis. Hepatology 52(5):1836–1846, 2010. doi: 10.1002/hep.31518.

TROVATO, F.M., MARTINES, G.F., CATALANO, D., MUSUMECI, G., PIRRI, C., TROVATO, G.M. Echocardiography and NAFLD (non-alcoholic fatty liver disease). Int J Cardiol 221:275–279, 2016. doi: 10.1016/j.ijcard.2016.06.180.

VAN HERPEN, N.A., SCHRAUWEN-HINDERLING, V.B. Lipid accumulation in non-adipose tissue and lipotoxicity. Physiol Behav 94(2):231–241, 2008. doi: 10.1016/j.physbeh.2007.11.049.

VANWAGNER, L.B., WILCOX, J.E., COLANGELO, L.A., LLOYD-JONES, D.M., CARR, J.J., LIMA, J.A. et al. Association of nonalcoholic fatty liver disease with subclinical myocardial remodeling and dysfunction: A population-based study. Hepatology 62(3):773–783, 2015. doi: 10.1002/hep.27869.

VANWAGNER, L.B., WILCOX, J.E., NING, H., LEWIS, C.E., CARR, J.J., RINELLA, M.E. et al. Longitudinal Association of Non‐Alcoholic Fatty Liver Disease With Changes in Myocardial Structure and Function: The CARDIA Study. J Am Heart Assoc 9(4), 2020. doi: 10.1161/JAHA.119.014279.

WANG, Q., MA, W., XIA, J. Nonalcoholic Fatty Liver Is Associated With Further Left Ventricular Abnormalities in Patients With Type 2 Diabetes Mellitus: A 3-Dimensional Speckle-Tracking Study. J Ultrasound Med 37(8):1899–1911, 2018. doi: 10.1002/jum.14536.

WHITE, D.L., KANWAL, F., EL–SERAG, H.B. Association Between Nonalcoholic Fatty Liver Disease and Risk for Hepatocellular Cancer, Based on Systematic Review. Clin Gastroenterol Hepatol 10(12):1342-1359.e2, 2012. doi: 10.1016/j.cgh.2012.10.001.

WIJARNPREECHA, K., LOU, S., PANJAWATANAN, P., CHEUNGPASITPORN, W., PUNGPAPONG, S., LUKENS, F.J. et al. Association between diastolic cardiac dysfunction and nonalcoholic fatty liver disease: A systematic review and meta-analysis. Dig Liver Dis 50(11):1166–1175, 2018. doi: 10.1016/j.dld.2018.09.004.

YOUNOSSI, Z.M., KOENIG, A.B., ABDELATIF, D., FAZEL, Y., HENRY, L., WYMER, M. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology 64(1):73–84, 2016. doi: 10.1002/hep.28431.

YOUNOSSI, Z.M., STEPANOVA, M., YOUNOSSI, Y., GOLABI, P., MISHRA, A., RAFIQ, N. et al. Epidemiology of chronic liver diseases in the USA in the past three decades. Gut 69(3):564–568, 2020. doi: 10.1136/gutjnl-2019-318813.

YU, X-W., CHEN, Q., KENNEDY, R.H., LIU, S.J. Inhibition of sarcoplasmic reticular function by chronic interleukin-6 exposure via iNOS in adult ventricular myocytes. J Physiol 566(2):327–340, 2005. doi: 10.1113/jphysiol.2005.086686.

ZAMIRIAN, M., SAMIEE, E., MOAREF, A., ABTAHI, F., TAHAMTAN, M. Assessment of subclinical myocardial changes in non-alcoholic fatty liver disease: A case-control study using speckle tracking echocardiography. Iran J Med Sci 43(5):466–472, 2018.

Downloads

Publicado

2021-03-29

Como Citar

Nascimento, M., Gregolin, C. S., Luvizotto, R. A. M., Cicogna, A. C., & Nascimento, A. F. (2021). Relação entre doença hepática gordurosa não alcoólica e alterações cardíacas. Scientific Electronic Archives, 14(4), 70–87. https://doi.org/10.36560/14420211248